secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2026-08-06T20:05:21+00:00
Accession:  0001604821-26-000015
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q2 revenue $752.8M (+37.7% YoY); raises FY2026 guidance by $100M
-----------------------------------------------------------------------

- Revenue $752.8M (+37.7% YoY); tests processed 1,043,900 (+22.4%); oncology tests 296,700 (+57.2%).
- Net loss $67.0M ($0.47 diluted EPS) vs $100.9M ($0.74) in Q2 2025; operating loss $75.8M vs $110.4M.
- Raised 2026 annual revenue guidance by $100M midpoint to $2.85B-$2.91B; gross margin ~64-66%.
- Cash increased $3.6M in Q2 to $1,091.5M; debt $80.3M under UBS line at SOFR+50bps.
- CEO cites Signatera regulatory approvals, Medicare coverage for Prospera, and Panorama NIPT launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000160482126000015/0001604821-26-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000160482126000015/ntra-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001604821-26-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer